ASCO Audio Journal of Oncology in Advance – June 15th, 2007 – reporting from: ASCO Annual Meeting, Chicago, June 1-5, 2007
Christiane Kuhl
Julie Gralow
MRI Better Than Mammography for Detecting High-Grade Ductal Carcinoma In Situ?
REFERENCE: 1504, ASCO Annual Meeting Chicago June 1-5, 2007
CHRISTIANE KUHL, University of Bonn, Germany
COMMENT: JULIE GRALOW, University of Washington, Seattle
The ASCO meeting in Chicago heard findings from Germany that suggested MRI was better than mammography for the detection of ductal carcinoma in situ, or preinvasive breast cancer. Derek Thorne spoke to Christiane Kuhl, from the University of Bonn, about her team’s provocative data, while Julie Gralow of the University of Washington commented on how this study could affect clinical practice.
CHRISTIANE KUHL, University of Bonn, Germany
COMMENT: JULIE GRALOW, University of Washington, Seattle
The ASCO meeting in Chicago heard findings from Germany that suggested MRI was better than mammography for the detection of ductal carcinoma in situ, or preinvasive breast cancer. Derek Thorne spoke to Christiane Kuhl, from the University of Bonn, about her team’s provocative data, while Julie Gralow of the University of Washington commented on how this study could affect clinical practice.
Priya Rastogi
No Increase in Time of Cardiac Toxicity From Trastuzumab
REFERENCE: LBA 513, ASCO Annual Meeting Chicago June 1-5, 2007
PRIYA RASTOGI, University of Pittsburgh
COMMENT: JULIE GRALOW, University of Washington, Seattle
The latest data from the large NSABP B-31 trial, which looked at trastuzumab in breast cancer, have provided some reassurance that the drug’s cardiac toxicity does not continue to grow over time. Priya Rastogi of the University of Pittsburgh School of Medicine told Derek Thorne about the findings, and she also explained her group’s new model, which could help doctors assess the risk to patients in this situation. Julie Gralow commented on her findings.
PRIYA RASTOGI, University of Pittsburgh
COMMENT: JULIE GRALOW, University of Washington, Seattle
The latest data from the large NSABP B-31 trial, which looked at trastuzumab in breast cancer, have provided some reassurance that the drug’s cardiac toxicity does not continue to grow over time. Priya Rastogi of the University of Pittsburgh School of Medicine told Derek Thorne about the findings, and she also explained her group’s new model, which could help doctors assess the risk to patients in this situation. Julie Gralow commented on her findings.
To listen this episode please go to ASCO Audio Journal of Oncology in Advance Presentations.
